| Budget Amount *help |
¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
Fiscal Year 2011: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2010: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2009: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
|
|---|
| Research Abstract |
1) Analysis of severe congenital neutropenia-derived iPS cells(SCN-iPS cells) Clonal hematopoietic assay indicated that SCN-iPS cells had a significantly decreased capability to generate neutrophil colonies, which contained few mature neutrophils, reflecting the feature of SCN. Since the expression of WNT/b-Catenin pathway-related genes were decreased, we added WNT3a to hematopoiesis-indunction culture. WNT3a stimulated the maturation of SCN-iPS cell-derived neutrophils. These results suggested the possibility of treatment of SCN using WNT3a.
2) Analysis of Down syndrome-derived iPS cells(DS-iPS cells) Clonal hematopoietic assay indicated that DS-iPS cells had increased capabilities to generate all types of definitive hematopoietic/blood cells. Microarray analysis also demonstrated an increased expression of RUNX1 on chromosome 21, which was confirmed by RT-PCR. These results indicated that hematopoietic abnormalities in DS patients might relate with the increased expression of RUNX1, which could be a target gene for the treatment of hematopoietic disorders in patients with Down syndrome.
|
